Levetiracetam's inhibition of synaptic vesicle glycoprotein 2A and alteration of GABA metabolism and turnover in the striatum may contribute to dyskinesia by influencing striatal dopamine release [15]. This evidence concerns the gene SV2A and Dyskinesia.